Digital Dose Inhaler Market Set to Garner High Revenues Owing to Increasing Prevalence of Respiratory Diseases
Digital Dose Inhaler Market |
The digital dose inhaler market is anticipated to
witness substantial growth due to rising cases of respiratory diseases across
the globe. Digital dose inhalers help in delivery of medication directly to the
airways through deep inhalation. These devices address issues with traditional
pressurized metered dose inhalers and dry powder inhalers such as inadequate
coordination between actuation and inhalation. Digital dose inhalers offer dose
counter integration, connectivity capabilities, and customizable dose reminders
which help patients in effective therapy management of asthma and chronic
obstructive pulmonary disease (COPD). The Global Digital Dose Inhaler Market is
estimated to be valued at US$ 18.33 Bn
in 2024 and is expected to exhibit a CAGR
of 19% over the forecast period 2024
To 2031.
Key Takeaways
Key players operating in the Digital
Dose Inhaler Market Demand are 3M, AstraZeneca, GLENMARK
PHARMACEUTICALS LTD., Novartis AG, Sensirion AG, Propeller Health, OPKO Health,
Inc., Teva Pharmaceutical Industries Ltd., BEXIMCO Pharmaceuticals, GSK plc.,
Mundipharma International, Honeywell International Inc., Veranex, Cognita Labs.
3M, AstraZeneca and Novartis AG currently dominate the market.
The digital dose inhalers offer various opportunities such as integration of
dose counters and connectivity capabilities in traditional inhalers. This
feature allows patients to digitally track medication use and share data with
physicians. The connectivity further enables physicians to remotely monitor
patients and optimize treatment plans.
The major players are focusing on global expansion to consolidate their market
presence. For instance, in 2021, Propeller Health expanded into Germany by
partnering with global pharmaceutical company Teva. Similarly, Cognita Labs has
collaborations in Europe and Asia to commercialize its digital inhaler
products.
Market drivers: Rising patient
non-adherence to inhaler medications due to complex treatment regimens is a key
factor driving adoption of smart inhalers. Integrated features in digital dose
inhalers help users adhere to prescribed treatments and therapy plans.
Market restraints: High product and development costs associated with digital
dose inhalers limit their widespread adoption. Further, availability of generic
versions of conventional inhalers at lower prices poses pricing challenges for
digital variants. Lack of internet connectivity or digital skills in certain
regions also restraint market potential currently.
Segment
Analysis
The digital dose inhaler market can be segmented based on product type,
application, end user and region. By product type, the dry powder inhalers
segment is expected to dominate during the forecast period as they are user
friendly and easier to carry for patients as compared to other inhaler types.
By application, the asthma segment accounts for the largest market share
currently due to the high prevalence of asthma across the globe. Hospitals
dominated the end user segment in 2024 as digital dose inhalers are prescribed
majorly during hospital visits or when asthma exacerbations occur.
Global Analysis
Regionally, North America holds the highest share of the digital dose inhaler
market and is expected to remain dominant during the forecast period. This is
majorly due to well-established healthcare infrastructure and rising healthcare
expenditure in the region. However, Asia Pacific is expected witness the
highest growth rate owing to fast adoption of advanced technologies, growing
pollution levels and increasing healthcare expenditure in emerging countries
such as China and India. Key players are focusing on expanding their digital
dose inhaler portfolio and entering partnerships to strengthen their market
presence across different regions globally.
Get more insights on Digital Dose Inhaler Market
Comments
Post a Comment